Research progress on the relationship between glucagon-like peptide-1 receptor agonist and metabolic associated fatty liver disease
10.3969/j.issn.1006-6187.2025.06.013
- VernacularTitle:胰高血糖素样肽1受体激动剂与代谢相关脂肪性肝病相关性的研究进展
- Author:
Haitao LI
1
;
Zhikai XU
;
Yu GAO
Author Information
1. 067000 承德医学院研究生学院
- Publication Type:Journal Article
- Keywords:
Metabolic associated fatty liver disease;
Glucagon-like peptide 1 receptor agonist;
Obesity
- From:
Chinese Journal of Diabetes
2025;33(6):472-475
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease(MAFLD)is a metabolic disorder liver disease closely related to insulin resistance(IR)and genetic susceptibility.Hepatocyte steatosis is the main pathological change.In recent years,the prevalence of MAFLD has increased significantly,so it is necessary to provide interventions as soon as possible.Glucagon-like peptide-1 receptor agonist plays a hypoglycemic effect by promoting insulin release and reducing IR.Studies shows that it has significant benefits on body weight,lipid metabolism,inflammation and fibrosis in patients with MAFLD,and is expected to be an effective drug for the treatment of MAFLD.
